1 Min Read
April 25 (Reuters) - Biogen Inc reported a 3 percent rise in quarterly revenue, helped by higher-than-expected sales of its newly launched spinal muscular atrophy drug, Spinraza.
However, net income attributable fell to $747.6 million, or $3.46 per share, in the first quarter ended March 31, from $970.9 million, or $4.43 per share, a year earlier.
Total revenue rose to $2.81 billion from $2.73 billion. (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)